Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 TrialKoji Sasaki, Elias Jabbour, Marina Konopleva et al.|Blood|2018Cited by 17
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First RelapseKoji Sasaki, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2019Cited by 13
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II StudyNicholas J. Short, Hagop M. Kantarjian, Elias Jabbour et al.|Blood|2018Cited by 12
Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II TrialFadi Haddad, Hagop M. Kantarjian, Elias Jabbour et al.|Blood|2023Cited by 11